|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 275.30 EUR | +4.52% |
|
+4.71% | +16.38% |
| 06-05 | Glenmark Pharmaceuticals Launches Generic Seizure Drug in US | MT |
| 06-04 | UCB and Biogen Inc. Demonstrate Clinical Profile of Dapirolizumab Pegol in Systemic Lupus Erythematosus At EULAR 2026 | CI |
| Market Cap | 51.59B 59.45B 47.55B 44.56B 83.25B 5,692B 84.99B 567B 220B 2,744B 223B 218B 9,540B | P/E Ratio 2026 * |
29.2x | P/E Ratio 2027 * | 22.4x |
|---|---|---|---|---|---|
| Enterprise Value | 50.46B 58.15B 46.52B 43.59B 81.44B 5,568B 83.14B 555B 215B 2,684B 218B 214B 9,332B | EV / Sales 2026 * |
5.92x | EV / Sales 2027 * | 5.04x |
| Free-Float |
61.59% | Yield 2026 * |
0.54% | Yield 2027 * | 0.56% |
Last Transcript: UCB
| 1 day | +4.52% | ||
| 1 week | +4.71% | ||
| Current month | +12.51% | ||
| 1 month | +16.98% | ||
| 3 months | +8.70% | ||
| 6 months | +13.34% | ||
| Current year | +16.38% |
| 1 week | 258.2 |  | 273.5 |
| 1 month | 229.2 | | 273.5 |
| Current year | 223 | | 285.4 |
| 1 year | 153.75 | | 285.4 |
| 3 years | 65.68 | | 285.4 |
| 5 years | 65.68 | | 285.4 |
| 10 years | 55.45 | | 285.4 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 67 | 2014-12-31 | |
Sandrine Dufour
DFI | Director of Finance/CFO | 59 | 2020-06-30 |
Alistair Henry
CTO | Chief Tech/Sci/R&D Officer | 59 | 2024-04-30 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 55 | 2011-12-31 | |
| Director/Board Member | 67 | 2014-12-31 | |
| Director/Board Member | 56 | 2014-04-23 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +4.52% | +4.71% | - | - | 59.45B | |
| +1.63% | -2.74% | +17.91% | -18.09% | 62.21B | |
| -0.92% | +28.60% | +28.60% | +28.60% | 38.9B | |
| +0.26% | +9.80% | -55.40% | -65.15% | 36.4B | |
| +2.94% | +1.79% | +50.28% | -35.26% | 29.52B | |
| +2.32% | +6.51% | +56.62% | +76.65% | 21.54B | |
| +7.94% | -3.78% | +78.88% | -59.73% | 19.7B | |
| +4.80% | -0.20% | -5.33% | +112.95% | 16.18B | |
| -1.00% | -2.96% | +47.82% | +98.81% | 15.89B | |
| +0.22% | +0.33% | +72.98% | +322.19% | 13.23B | |
| Average | +2.27% | +1.00% | +32.48% | +51.22% | 28.18B | |
| Weighted average by Cap. | +2.24% | +1.19% | +24.08% | +18.57% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 8.52B 9.82B 7.85B 7.36B 13.75B 940B 14.04B 93.69B 36.27B 453B 36.86B 36.06B 1,576B | 9.63B 11.1B 8.88B 8.32B 15.54B 1,062B 15.86B 106B 40.99B 512B 41.65B 40.76B 1,781B |
| Net income | 1.75B 2.02B 1.61B 1.51B 2.83B 193B 2.88B 19.25B 7.45B 93.13B 7.57B 7.41B 324B | 2.27B 2.62B 2.1B 1.96B 3.67B 251B 3.75B 25.01B 9.68B 121B 9.84B 9.63B 421B |
| Net Debt | -1.12B -1.29B -1.04B -970M -1.81B -124B -1.85B -12.35B -4.78B -59.73B -4.86B -4.75B -208B | -3.1B -3.58B -2.86B -2.68B -5.01B -342B -5.11B -34.12B -13.21B -165B -13.42B -13.13B -574B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-06-12 | 273.50 € | +3.83% | 0 |
| 26-06-11 | 263.40 € | +0.11% | 0 |
| 26-06-10 | 263.10 € | +1.04% | 0 |
| 26-06-09 | 260.40 € | -0.08% | 0 |
| 26-06-08 | 260.60 € | -0.23% | 8 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- UCB Stock
- UNC Stock
Select your edition
All financial news and data tailored to specific country editions
